An interesting international clinical trial has now opened in the UK and is recruiting patients. The CARE1 clinical trial will look at how different groups of patients respond to 1st line treatment with the intention of discovering which patients are more likely to respond to which combination of drugs.

With the use of biomarkers, the results of this study will hopefully tell us which medicines work best for individual patients. This will remove the need for trial and error when selecting the best treatment option, reducing the time and money that is used to find the best treatment.

The International Kidney Cancer Coalition (IKCC) and Action Kidney Cancer are represented on the Trial Management Committee of this important international study.

The study is now on our clinical trial database. The first site to open is Prof Tom Powles at Queen Mary's Hospital in London. Nine further sites are planned for the UK - watch this space!

For more information, please visit our clinical trial database here:

Following on from the Safe Sick Pay campaign that Steve Pointon from Action Kidney Cancer was involved with, Steve was asked to share is story with Mission Remission for a series of articles and interviews about the financial implications of a cancer diagnosis.

Read Steve's engaging story on our website here:

Pressure on NHS cancer services has been increasing, causing delays in access for patients.

Quick cancer testing, diagnosis, and treatment reduce stress and improve outcomes, especially when cancer is caught early.

December 2023 marked the first report of cancer waiting times based on new NHS England targets. Cancer Research UK’s latest article shares the results for March 2025 in England.

Read more on our website here:

As a charity we have noticed that more younger people are coming to us with a diagnosis of kidney cancer. Our concerns have been realised in a study conducted by American researchers, which has identified an increase in the incidence of breast, bowel, womb, pancreatic, and kidney cancers in individuals under 50 years of age.

Read more on our website here: